8 results
The first aim of the study is to investigate whether DCS addition to exposure therapy enhances symptom reduction in PD+AGO. The second objective of the study is to establish the optimal timing of administration of DCS (30 minutes before or directly…
treatment outcome in OCD. Objective: The objective for this study is fourfold. First we will determine whether DCS addition to behavioural exposure therapy may enhance fear extinction and improve symptoms in OCD. Our hypothesis is that improvement…
The objective for this study is threefold. First we will determine whether DCS addition to behavioural exposure therapy may enhance fear extinction and improve symptoms in BDD. Our hypothesis is that improvement will occur and at a faster rate than…
The aim of this pilot-study is to establish the potential efficacy of acute doses of 50 mgs D-cycloserine (DCS), a partial NMDA agonist, in accelerating and/or augmenting the effect of exposure and response prevention (ERP) in the treatment of…
The present study is aimed at testing the effects of D-cycloserine in addition to exposure treatment sessions in PTSD patients, in a randomized double blind placebo controlled study.
The primary objective is to test the role of NMDA receptor-dependent learning in an experimental model of conditioned nocebo effects on self-reported pain (sub-study 1) and itch (sub-study 2). Secondary objectives are to examine the role of NMDA…
To assess the safety and feasibility of a multimodal combination of FLOT CT with CROSS
The primary objective is to demonstrate superiority of neoadjuvant systemic therapy followed by repeat local treatment as compared to upfront repeat local treatment in patients with at least one locally treatable recurrent CRLM in the absence of…